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Abstract (215 words) 1 
Fatty acids are among the most studied nutrients in human metabolism and health. 2 
Endogenous fatty acid status influences health and disease via multiple mechanisms at 3 
all stages of the life cycle. Despite the widespread interest, attempts to summarize the 4 
results of multiple studies addressing similar fatty acid related outcomes via meta-5 
analyses and systematic reviews have been disappointing, largely because of 6 
heterogeneity in study design, sampling, and laboratory and data analyses. Our 7 
purpose is to recommend best practices for fatty acid clinical nutrition and medical 8 
studies. Key issues in study design include judicious choice of sampled endogenous 9 
pools for fatty acid analysis, considering relevant physiological state, duration of 10 
intervention and/or observation, consideration of specific fatty acid dynamics to link 11 
intake and endogenous levels, and interpretation of results with respect to known fatty 12 
acid ranges. Key laboratory considerations include proper sample storage, use of 13 
sample preparation methods known to be fit-for-purpose via published validation 14 
studies, detailed reporting or methods to establish proper fatty acid identification and 15 
quantitative analysis including calibration of differential response, quality control 16 
procedures, and reporting of data on a minimal set of fatty acids to enable 17 
comprehensive interpretation. We present a checklist of recommendations for fatty acid 18 
best practices to facilitate design, review, and evaluation of studies with the intention of 19 
improving study reproducibility.  20 
Keywords. Meta-analysis; systematic review; experimental design; protocol; placebo; 21 
sample preparation; gas chromatography; fatty acid methyl esters; response factors.  22 
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1.0 Introduction 23 
Fatty acids are among the most studied nutrients and bioactive compounds. A 2017 24 
PubMed search on the specific term “fatty acids” limited to human and clinical trials 25 
exceeds 24,000 hits. Fatty acid intake influences all aspects of health and disease 26 
because of their diverse roles as structural lipids in every cell, signaling precursors, and 27 
as the major component of oily secretions on the skin and elsewhere. The rich 28 
preclinical literature developed in cells and animals on the metabolism, biochemistry 29 
and molecular biology, biophysics, and genetics of fatty acids indicates that the choice 30 
of dietary fats is a key modifiable factor determining proper development, and best 31 
health, through the life course. 32 
Despite the dozens of peer reviewed reports appearing weekly, standardization of the 33 
many parameters and considerations common to fatty acid studies has not been 34 
undertaken. Meta-analyses and systematic reviews have produced mixed results due to 35 
heterogeneity between studies. Heterogeneity reflecting true physiologic or intervention 36 
differences is important in translating findings into recommendations and dietary 37 
guidance. Heterogeneity due to study design, fatty acid biochemical analysis, and 38 
reporting obscures true differences and reduces the strength of overall evidence. 39 
Therefore, the best practices presently described are intended to inform design, 40 
implementation, and reporting of human clinical studies investigating fatty acid 41 
metabolism and function so that consistency and strength of the totality of evidence 42 
reflect physiologic rather than methodologic differences. Our goal is to guide choices 43 
and recommend reporting standards that reveal issues that can lead to apparent but not 44 
real differences in outcomes, rather than to be all inclusive. 45 
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The report consists of two sections, a narrative discussing various considerations in the 46 
design and implementation of fatty acid studies and a Best Practices Recommendation 47 
list (Table 2) intended for use in planning, evaluating, and reporting studies in humans 48 
dealing with fatty acid analyses. Practices are based on the experiences of the co-49 
authors with input from fatty acid researchers worldwide who submitted comments. 50 
1.1 Scope 51 
The recommendations are meant to be adopted as appropriate by various stakeholders 52 
in fatty acid studies – researchers, reviewers, readers, and are not intended to be 53 
prescriptive. The extent to which recommendations are applied directly depends on the 54 
specific issues investigated in each study. Principal investigators and their research 55 
team members are ultimately responsible for design and conduct of studies taking into 56 
account all factors relevant to the hypotheses or research questions to be investigated. 57 
Hundreds of fatty acids are present in human plasma, derived from diet and 58 
metabolism. Clearly it is not possible to consider all issues relevant to all fatty acids in a 59 
limited document. The focus here is on fatty acids that have been of greater interest in 60 
clinical studies measuring circulating fatty acids with chain lengths from 14 to 24 61 
carbons. This includes examinations of saturated, monounsaturated, polyunsaturated 62 
(PUFA) as well as long-chain PUFA (≥20 carbons, ≥2 carbon-carbon double bonds, 63 
LCPUFA) or highly unsaturated fatty acids (≥ 3 carbon-carbon double bonds, HUFA).  64 
We chose not to consider fatty acids of chain length 12 carbons and lower to avoid 65 
methodological issues particularly with regard to the volatility of fatty acid methyl esters 66 
(FAME) of these shorter chain fatty acids. In its initial study, the National Institutes of 67 
Standards and Technology (NIST) fatty acid quality assurance program (FAQAP) 68 
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involving dozens of fatty acid analysis labs used a similar range and reasoning, as 69 
outlined below. Subsequent studies revealed that a minority of laboratories report fatty 70 
acids C12 and lower. Specific methods are required to avoid uncontrolled losses of 71 
short (1) and medium (2) chain fatty (organic) acids and would unnecessarily complicate 72 
the present document. However, the principles should be highly relevant to studies 73 
involving these fatty acids, as well as those with greater than 24 carbons. 74 
2.0 Fatty acid trials. The independent variable. 75 
Although chemically speaking the term “fatty acid” refers to the free acid, the biomedical 76 
literature overwhelmingly uses the term to refer to fatty acyl or fatty ether species as 77 
well as non-esterified fatty acids (NEFA, also called “free fatty acids”, FFA), as a 78 
shorthand nomenclature to refer to all fatty acids liberated as a result of an acid or base 79 
lipolysis of a biological sample.(3)  Based on the clear chemical meaning of NEFA and 80 
FFA, the term “fatty acid” is best reserved for all acyl groups in a sample regardless of 81 
lipid class.  82 
Fatty acids are endogenous biomolecules, macronutrients, and n-3 alpha-linolenic and 83 
n-6 linoleic acid are essential nutrients. As such they differ from xenobiotics – drugs and 84 
toxins – that do not occur widely in humans. Without exception, endogenous 85 
compounds are handled by specific metabolic mechanisms evolved to regulate 86 
concentration and distribution and have required roles in healthy humans. Xenobiotics 87 
in contrast are optional compounds that are normally not at appreciable concentrations 88 
unless purposefully ingested. The term “drug” is also a regulatory term that is applied to 89 
fatty acids when they are an active ingredient component of a preparation that is 90 
approved via a drug regulatory scheme. We note, however, that this does not change 91 
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the fundamental character of fatty acids as nutrients. As nutrients, the diverse and 92 
highly regulated character of fatty acids must be figured into any study design and 93 
interpretation, including for instance, known concentration ranges in healthy 94 
populations, enzyme-mediated interconversions, and de novo versus exogenous origin.  95 
Drugs undergo extensive preclinical formulation and testing for safety and efficacy prior 96 
to being permitted to be used in humans. Formulations in particular are carefully defined 97 
according to good manufacturing practice (GMP), requiring extensive documentation of 98 
starting materials, procedures for creating the specific drug including all excipients, and 99 
specifications for allowed concentrations of components in the final drug. In contrast, 100 
studies of fatty acids in foods or supplements routinely rely on generic labeling 101 
information to define composition. Omission of the actual analysis of the test article, the 102 
target oil under investigation, for both quantity and quality of the putative active 103 
ingredients, may be a major source of response variability. 104 
Recommendation 105 
1) Treatment fatty acids. All fatty acids in the food or supplements relevant to the 106 
issue under investigation must be analyzed and defined. 107 
2.1 Rationale for choice of fatty acid pool 108 
Numerous circulating fatty acids pools can be sampled, each with their own properties 109 
(4). When the primary outcome the pool must be specified prior to the study initiation for 110 
power calculations. The 2016 Global map study reported that about 90% of studies 111 
reported at least one of three blood pools; plasma total lipids (TL), plasma 112 
phospholipids (PL), and red blood cells (RBC) (5). In recent years, total blood lipids 113 
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derived from dried blood spots have become prominent for their simplicity of collection 114 
and storage. Each of these pools, however, has its inherent strengths and limitations 115 
and, as such, the rationale for choosing the most appropriate pool should be based on 116 
the research design used and the specific question being asked. We discuss here 117 
strengths and limitations of the blood pools emphasizing the three most studied pools. 118 
We also discuss how to choose the blood pool in which the fatty acids will be analyzed 119 
based on the three main types of research designs and what type of question will be 120 
answered when analyzing fatty acid profile in these various pools.  121 
2.1.1 Plasma total lipids 122 
The plasma total lipid pool has logistical advantages for fatty acid analysis, but can 123 
present challenges in interpretation. Specifically, plasma sample collection tends to be 124 
routine in clinical studies, and the fatty acids in the sample can be relatively stable. 125 
Plasma fatty acids are found in various pools including FFA bound and unbound to 126 
albumin, and fatty acyls in complex (acylated) lipids of the lipoproteins. The bulk of the 127 
complex lipids consist of triacylglycerols (49%), PLs (24%), and cholesteryl esters 128 
(16%) (6) which can vary slightly based on the population (4). The triacylglycerol and 129 
cholesteryl ester pools have considerable influence on plasma total lipid fatty acid 130 
composition. Plasma total lipids tend to have n-6 linoleic acid (18:2n-6) as the dominant 131 
fatty acid, in excess of palmitic acid (16:0), and oleic acid (18:1n-9) tends to be more 132 
abundant than stearic acid (18:0) (Figure 1). The plasma total lipid fatty acid amounts 133 
can vary considerably compared to relevant mean treatment effects within and across 134 
individuals. These are largely due to gene-diet and gene-environment influences on 135 
lipoproteins and the triacylglycerol pool that include fasting or the sample timing relative 136 
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to dietary intake, specifically the types and amounts of foods and/or supplements 137 
consumed, as well as genetic polymorphisms (7). Therefore, when using fatty acid data 138 
from plasma total lipids, quantification of a comprehensive range of fatty acids is 139 
recommended to enable proper interpretation, as discussed below. 140 
2.1.2 Plasma PLs (PL) 141 
Plasma PL fatty acid determinations take advantage of the availability and stability of 142 
plasma blood sample collections. The isolation and focus on the plasma PL pool 143 
eliminates the variability introduced by the transient postprandial triacylglycerol pool and 144 
the resulting fatty acid composition is believed to better represent cell membrane fatty 145 
acid composition. However, plasma PL are more highly concentrated in 146 
phosphatidylcholines found in the lipid monolayer of lipoproteins, and as a result plasma 147 
PLs measurements can be a biased view of the fatty acid composition of lipid bilayers. 148 
Specifically, phosphatidylethanolamine, a dominant PL of the inner bilayer (6) has a 149 
distinct fatty acid profile in various tissues (8-11). This results in plasma PL tending to 150 
be higher in n-6 linoleic acid and lower in n-6 arachidonic acid (20:4n-6) as compared 151 
with fatty acid compositions from sources with lipid bilayers (Figure 1). Logistically, the 152 
requirement for additional separation techniques such as thin layer chromatography, 153 
preparative liquid chromatography, or solid phase extraction (12) can decrease 154 
analytical throughput, especially in very large sample sets. However, single-step 155 
selective lipid class extraction protocols using polar solvents (e.g., methanol) are 156 
available to isolate PLs and have high throughput potential (13).    157 
2.1.3 Erythrocytes 158 
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Erythrocytes have a distinct advantage as the main blood pool with a lipid bilayer with a 159 
more complete spectrum of PL classes and therefore a fatty acid composition that may 160 
better reflect cell membranes of biological tissues (4, 6). Erythrocyte total lipid and fatty 161 
acid content is also relatively stable when compared with plasma (14), although this 162 
stability is often overestimated (see below). Sample collection, storage and preparation 163 
of erythrocytes can, however, be problematic (15). Specifically, plasma and serum tend 164 
to be collected as the primary blood sample for clinical studies in general (16), the heme 165 
content of erythrocytes can promote the oxidation of PUFA unless preventative steps 166 
are taken (17). Erythrocyte lysis, extended extraction times, reduced chloroform-167 
methanol ratios or the use of isopropanol rather than methanol, are needed to maximize 168 
erythrocyte lipid recovery (18, 19). Erythrocyte fatty acid profiles are often considered a 169 
better long-term marker of dietary fatty acid habits based on the life span of erythrocytes 170 
(20) and the half-life of fatty acids in erythrocytes as compared with serum cholesteryl 171 
esters (21). However, there is evidence that half-life of palmitate is quite short in 172 
erythrocytes (less than 30 min for some acylated erythrocyte proteins, 7-9 h for 173 
erythrocyte PLs) (22). With fish oil feeding, EPA can increase more rapidly than 174 
erythrocyte turnover, within four weeks and possibly as soon as one week, while 175 
increases in DHA are subtle (23). In a sporadic fish oil supplementation trial mimicking 176 
UK fish intake patterns, the dose relationship of EPA in erythrocytes was also relatively 177 
weak (24). This is likely due to differences in the incorporation of EPA and DHA into 178 
lipid classes (phosphatidylcholine versus phosphatidylethanolamine) and/or 179 
sequestering into the outer versus inner membrane bilayers (25). It is important to note 180 
that the fast incorporation of EPA into erythrocytes may result in the masking of non-181 
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adherence to long-term fish oil intervention when the only n-3 PUFA biomarkers that are 182 
monitored are sums or composites of different n-3 PUFA such as EPA+DHA (26). 183 
Overall in erythrocytes, because the PL concentration dominates over triacylglycerols, 184 
the fatty acid composition tends to have lower percentages of 18:2n-6, while stearic, 185 
oleic, arachidonic and docosahexaenoic acids tend to be higher (Figure 1).  186 
2.1.4 Other pools derived from whole blood 187 
Fatty acids in other blood pools are also available and their use may be warranted 188 
depending on the research goal and hypothesis (4). This includes lipid classes that can 189 
be isolated from plasma such as triacylglycerol and cholesteryl ester pools as 190 
mentioned previously but also the plasma NEFA (FFA) pool. The fatty acid composition 191 
of these plasma lipid classes are not reported as often as those of plasma PLs when 192 
examining long chain PUFA (27) but the cholesteryl ester pool has been used in several 193 
studies examining saturates, monounsaturates and 18 carbon PUFA (4, 28). However, 194 
unless a specific rationale is provided, reporting the fatty acid composition of cholesteryl 195 
esters is not advised since this pool is influenced by recent diet and fatty acyl substrate 196 
specificity of acyl-CoA-cholesterol acyl transferase and in particular lecithin-cholesterol 197 
acyl transferase (4). In addition, the fatty acid profile of other blood components such as 198 
white blood cells and platelets may be informative in certain situations (24, 27).   199 
2.1.5 Whole blood 200 
The use of whole blood sampling for fatty acid profiling is increasing (5). It has a distinct 201 
advantage in sample handling and processing as no separation is required, it is 202 
amenable to capillary blood collection (e.g. fingertip prick), and it can be collected and 203 
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preserved as a dried blood spot. Whole blood is, however, a comprehensive sample in 204 
that the fatty acids of the various blood components contribute to an overall fatty acid 205 
composition (Figure 1). In addition to plasma and erythrocytes, lipid structures in the 206 
buffy coat such as white blood cells and platelets are included. This can be 207 
disadvantageous as information about the sampled blood pool of the fatty acids is lost, 208 
limiting interpretation. Therefore, whole blood fatty acid composition may be influenced 209 
by hematocrit or changes in white blood cell pools due to infection, in addition to 210 
changes in plasma lipoproteins outlined above. 211 
Recommendation 212 
2) Sampled pool. Rationale for the choice of blood pool should be stated and justified 213 
with respect to biological research question, taking into account logistical issues with 214 
respect to study design. 215 
2.2 Randomized control trials (RCT) 216 
RCTs are an intervention study design in which outcomes from participants in one or 217 
several treatment group(s) are compared to those in a control group. Assignment of 218 
participants to treatment groups is random with the person assigning individuals to 219 
treatments and/or the participants being masked (blinded) or open depending on the 220 
hypothesis. RCT, usually considered a test required to establish causality, vary in 221 
duration from as brief as two weeks to as long as multiple years. As discussed below, 222 
equilibration times vary by pool and in some cases FA. 223 
Length of treatment: When establishing a rationale for selecting the blood pool in which 224 
fatty acid levels should be evaluated, length of treatment where dietary fat composition 225 
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is altered should be carefully considered. Indeed, dietary fatty acid concentrations 226 
change at different rates in the various pools within the circulation.  227 
Recommendation  228 
3) Intervention length. Intervention length should be rationalized based on the 229 
hypothesis.  230 
Rationales should refer specifically to whether the biological question responds on a 231 
short-term or long-term basis. For instance, a short-term intervention might seek to 232 
rapidly alter post-prandial lipemia, whereas a long-term intervention might seek to 233 
alter whole body status of PUFA for studies of chronic disease. In the latter case, 234 
reference should be made to the known timing of the disease etiology as justification 235 
to avoid spurious non-significant results because the term of exposure is too brief.  236 
Control/placebo oil. In all RCT, examination of fatty acid profiles in the circulation is 237 
essential for assessment of both the degree of integrity of the experimental procedures 238 
as well as the compliance level of individual participants. Important in such an 239 
evaluation is ensuring an adequate span of fatty acid contents of the oils chosen as 240 
treatments versus that of the control oil.  241 
Ideally, the fatty acids of the control oil should mimic the common diet of the country 242 
where the trial is conducted unless the investigators are purposely manipulating the diet 243 
without use of a control, such as would be the case with dietary fat replacement. 244 
Another point to consider in the rationale for choosing the appropriate control oil should 245 
include whether the participants have a special health condition such as pregnancy, 246 
cardiovascular risk, or cancer. For instance, high intakes of n-6 linoleic acid directly 247 
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suppress n-3 fatty acids at multiple levels (29, 30). Using placebo oils with PUFA very 248 
different than the population background diet, richer in n-6 or n-3 PUFA, may shift 249 
metabolism depending on dose and duration. The background diet of the study 250 
population should be considered when inferring effects to other populations, and in 251 
many cases may restrict application of the findings of the intervention to that specific 252 
population. A background diet containing the fatty acid of research interest can also 253 
affect the sample size required to achieve meaningful results. The commercial 254 
availability of fatty acid supplements can also cause compliance issues in treatment and 255 
control groups (31).  256 
Critical to deciding the fatty acid composition of a control oil is the question of fat 257 
substitution. In the instance of replacing one type of fat in the control for another type in 258 
the intervention, the non-trivial issue of whether any effect on health risk biomarkers is 259 
due to the addition of the test, or the removal of the control oil, must be considered. For 260 
instance, a PUFA-rich fat intervention test would be expected to lower cholesterol 261 
relative to a saturated fat control beyond that attributable PUFA relative a control PUFA 262 
or monounsaturated oil. A possible solution is to use a low-fat control, thus enabling the 263 
biological impact of the test fat in the intervention to be assessed without being 264 
confounded by the action of removing the control fat. However, in that instance either 265 
effects of the reduced energy level, and/or change due to other macronutrients, may 266 
confound assessment of the direct effect of the test fat on the biomarker of interest. As 267 
such, this issue of substitution of certain bioactive fatty acids for others has to be 268 
carefully examined when designing a clinical study and interpreting its results.  269 
Recommendation  270 
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4) Control composition. Control (comparator/placebo) doses should be chosen to be 271 
neutral with respect to the outcome, considering the known metabolism and levels of 272 
dietary fat with respect to the hypothesis and the study population.  273 
Blood fatty acids differ in their response to dietary fatty acid intake. For essential fatty 274 
acids such as n-3 alpha-linolenic acid, total fatty acid profiles shift to reflect changes in 275 
intake in ways that can be useful. For instance, n-3 alpha-linolenic acid levels 276 
expressed as percent total identified fatty acids increased over twofold following a 277 
controlled feeding period in humans of 4 weeks where over 20 g/d n-3 alpha-linolenic 278 
acid was consumed (32). However, for n-6 linoleic acid, the percent offsets in the 279 
circulating compartment were notably less (i.e. < 10%) even after substantially higher n-280 
6 fatty acid intakes, and for oleic acid rich diets the offsets were even more modest (i.e. 281 
<5%) following dietary substitutions containing high oleic acid canola oil with as high as 282 
72% oleic acid. This latter finding possibly reflects the non-essential nature of oleic acid; 283 
because this fatty acid is both synthesized de novo, manipulation of its levels in plasma 284 
and tissues is more resistant to changes in intake. 285 
Recommendation 286 
5) Biological responsiveness. The responsiveness of the target fatty acid pools 287 
should be considered with respect to the chosen intervention doses and duration. 288 
2.2.1 Ensuring adequate experimental execution and monitoring compliance  289 
The responsiveness of circulating fatty acid concentrations to interventions varies by 290 
specific fatty acid structure. As a general rule, fatty acids that can be synthesized de 291 
novo from carbon sources producing acetate (endogenous) are more difficult to 292 
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associate with dietary intake (exogenous) of the same fatty acids (4, 28, 33). As such, 293 
most saturated and monounsaturated fatty acids in blood tend to have weaker 294 
associations and inconsistent correlations to dietary intakes. Fatty acids that are 295 
primarily sourced from the diet tend to have stronger associations between blood and 296 
diet levels. While this includes n-3 and n-6 PUFA, it can also extend to other “unique” 297 
exogenous fatty acids such as odd-chain, branched chain fatty acids, as well as fatty 298 
acids with trans and conjugate bonds (4, 33). However, even with these dietary or 299 
“exogenous” fatty acids, the blood-diet relationship can be dictated by variation in 300 
endogenous fatty acid interconversion via C2 elongation, desaturation and beta-301 
oxidation metabolism of the specific fatty acids of interest. For example, within the 302 
PUFA families, blood EPA and DHA correlate strongly with dietary intake of EPA and 303 
DHA, while n-6 arachidonic acid in blood and intake are less responsive (4), suggesting 304 
other factors such as intake of other dietary fatty acids (i.e. 18:2n-6) and metabolic flux 305 
have significant influence on n-6 arachidonic acid blood status (33). Blood fatty acids 306 
may also provide insight into shifts in other macronutrient intakes as increased n-7 fatty 307 
acids and decreased 18:2n-6 have been associated with low fat/high carbohydrate diets 308 
as they represent a shift towards increased endogenous or de novo fatty acid 309 
production (34). 310 
Recommendation   311 
6) Fatty acid dynamics. Dietary fatty acid exposure and implications for well-312 
established principles of fatty acid metabolism must be taken into account for 313 
interpreting the diet-blood relationship.  314 
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For other types of interventions such as with n-3 fatty acid supplementation, blood fatty 315 
acid level shifts should be used to confirm that the experimental protocol had been 316 
correctly deployed, as well as an estimate of subject compliance. However, a more in-317 
depth benchmarking of anticipated shifts in the fatty acids of particular interest is 318 
required to best utilize this approach. In order to assess the utility of using circulating 319 
fatty acid levels as surrogates of ensuring experimental correctness and or compliance, 320 
it is necessary to explore what offsets would be expected in controlled dietary scenarios 321 
where specific fatty acid substitutions are made under compliance-assured conditions. 322 
Then, comparing observed offsets to what would be expected can inform investigators 323 
as to the degree of compliance of any particular participant in clinical trials. 324 
An excellent example of use of fatty acids to reflect protocol compliance is the case of 325 
DHA supplementation. In the absence of changes in other fatty acids, tissue DHA levels 326 
are largely governed by dietary intake as its synthesis from alpha-linolenic acid (ALA) is 327 
low under the industrial food supply’s dietary intake of competing linoleic acid (LA) (35, 328 
36). Circulating DHA levels in plasma total lipids, but not RBC, increase swiftly after 329 
DHA supplementation; for instance, volunteers consuming 4 g/d of DHA supplemented 330 
canola oil under compliance controlled conditions showed an increase in plasma total 331 
lipid DHA concentration of well over twofold over 4 weeks compared with the 332 
consumption of regular canola oil (32). The other means of raising circulating DHA, by 333 
lowering LA is slow. Any instance where DHA levels moved in opposite directions 334 
between control and DHA supplementation phases ought to signal problems in 335 
treatment assignment, blood collection procedures or subsequent experimentation 336 
stages. In instances of reverse responses of circulatory fatty acid levels to dietary 337 
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treatment assignments, investigators should scrutinize protocol execution to identify 338 
errors. Other studies show consistent deflections in DHA concentrations in blood 339 
subsequent to n-3 fatty acid feeding (37).  340 
Similarly, the sum of EPA and DHA levels in multiple circulating compartments in the 341 
blood has been utilized as a measure of compliance. Stark et al. demonstrated in a 342 
controlled supplement intervention study that sum of EPA + DHA in plasma PLs, 343 
erythrocytes and whole blood increases from 85-95 percent for every gram of EPA and 344 
DHA consumed over a negligible intake baseline (38). For intervention studies, 345 
available data suggest that certain fatty acid classes provide a better degree of 346 
representation of dietary intake shifts than do other classes as discussed below. These 347 
data are at variance with reported shifts within RBC and PL EPA and DHA levels within 348 
less well controlled feeding studies, where the responses were generally more gradual 349 
with increasing intakes, particularly at higher levels of EPA and DHA consumption (38). 350 
From those anticipated responses, target threshold values can be set to identify and 351 
possibly exclude study participants whose circulating fatty acid profiles fail to meet 352 
those thresholds, as an indicator of poor compliance. The failure of an individual’s 353 
circulating fatty acid level to meet an established threshold value is taken to imply that 354 
an inadequate proportion of the treatment fat was consumed. However, the degree of 355 
correspondence between circulating fatty acid levels and dietary intake will vary 356 
depending on the circulatory fatty acid compartment examined, whereby total circulating 357 
fatty acid levels would be expected to shift more rapidly over time relative to a more 358 
slowly turning over pool such as erythrocytes.  359 
2.2.2 Intent-to-treat (ITT) and Per-protocol (PP) analysis 360 
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A major source of heterogeneity among studies is perceived to be the de facto use of 361 
ITT rather than PP analysis, as well as imprecise application of the two approaches. 362 
Strictly interpreted, ITT analysis applies specifically to the entire treatment, for instance 363 
an entire caplet, regardless of whether the active ingredient was delivered to the 364 
participant. For example, an n-3 fatty acid supplement contained in a gel capsule that 365 
prematurely breaks causing high levels of fishy burping could result in lower compliance 366 
in the experimental group and bias toward the null compared to a properly functioning 367 
capsule supporting higher compliance.  368 
Trials of fatty acid intake accomplished with either foods or supplements are 369 
administered for the express purpose of altering the fatty acid profile of one or more 370 
endogenous tissues or fluids, usually intermediate to measuring a health outcome. 371 
During all trials, participants are consuming food with the target fatty acids and with 372 
other fatty acids that influence endogenous pools of fatty acids. Preparations that fail to 373 
sufficiently influence endogenous concentrations because, for instance, compliance is 374 
low, influence the dependent outcomes. Xenobiotics are appropriately analyzed on an 375 
Intent-to-treat (ITT) basis because they are inherently medical treatments with medical 376 
indications. ITT applies to the entire GMP defined treatment, and not exclusively to the 377 
test active ingredient. If no fatty acid measurements are made and a null result is found, 378 
the results cannot be ascribed to a failure of the test fatty acid(s) to induce an effect but 379 
only to the intervention as a whole. When no fatty acid measurements are made, such 380 
studies are particularly difficult to put into context of overall metabolism because 381 
changes in biological pools and biomarkers of compliance are undocumented. Per 382 
protocol (PP) analysis in contrast can effectively ignore many details of the preparation 383 
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and focus on establishing how changes in fatty acid levels in tissues correspond to 384 
changes in the health outcome. However, care must always be taken in interpretation of 385 
any PP to avoid assigning significance to reverse causality. Treatment outcome may be 386 
correlated with compliant participants, who in turn may be very different than non-387 
compliant participants in any number of uncontrollable lifestyle factors such as exercise, 388 
habitual diet, and smoking may render any effects to be group differences not 389 
ascribable to the fatty acid intervention. 390 
Recommendation  391 
7) Data analysis principles. All fatty acid intervention trials should report at least one 392 
measure of fatty acid concentration within a specified biological compartment so as to 393 
enable analysis on both an ITT and a PP basis. 394 
Nevertheless, the utility of using n-3 fatty acid levels in the circulating compartment as 395 
indicators of compliance is supported by these findings. Therefore, an important point 396 
here is that all RCT should indicate how compliance was monitored. Additionally, other 397 
types of research designs such as cross-over or sequential study design exist which 398 
these should use the same criteria as do RCT in selecting the most appropriate 399 
circulatory pool in which fatty acid profiles will be analyzed.  400 
Recommendation  401 
8) Fatty acid ranges. Intervention-based changes in circulating fatty acids should be 402 
compared with previous literature reports to establish that they fall into expected 403 
ranges.  404 
2.3 Observational. Prospective cohort studies (PCS) and cross-sectional studies. 405 
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PCS and many cross-sectional studies, for practical reasons, obtain samples over 406 
extended time periods, collecting biological samples for subsequent banking of those 407 
samples typically for several years in freezers at -80°C. Often a general lack of 408 
information exists in publications about the timing between when the biological samples 409 
were collected and when the fatty acid profile analysis was performed in the biological 410 
samples. For instance, some samples collected in the 1990s could have been analyzed 411 
less than two years after collection even though the paper was published in the 2000. 412 
However, for some studies, the samples may have been collected as early as the 1990s 413 
while the fatty acid analyses were performed in 2010, hence leaving a large gap 414 
between collection of samples and their subsequent analyses. An important question 415 
becomes whether sample quality persists after samples have been stored for so long 416 
and whether data are accurate, particularly in the case of n-3 fatty acid levels. Storage 417 
conditions are particularly important because practical considerations often require wide 418 
variability between sample collection and analysis, as for instance for enrollment of 419 
participants or sample collection over many months. Details about storage temperature 420 
and duration are provided below.  421 
Moreover, this type of study often reports dietary fat intake collected by dietary record or 422 
food frequency questionnaires. Some studies report dietary intakes in EPA+DHA 423 
evaluated from dietary recall or FFQ. In cross sectional studies circulating compartment 424 
fatty acid composition data can provide insight into habitual consumption patterns for 425 
dietary fats with far better accuracy than do dietary intake data. The substantial 426 
limitations of self-reported dietary intake assessment instruments have been identified 427 
by experts in that area (39). For instance, the content in EPA and DHA differs across 428 
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fish species and nearly always between farmed and wild fish (40, 41). In these types of 429 
studies, it is far more informative to look at fatty acid profiles within the circulating 430 
compartments rather than rely on the vagaries of recall methods and limitations of 431 
nutrient databases to identify dietary patterns of individuals. 432 
The rationale for choice of blood sample must reflect fatty acid status over the relevant 433 
time period. A representative example of fatty acids in circulation reflecting patterns of 434 
intake for fat qualitatively is seen in the case of the omega-3 index, which is intended to 435 
serve as a barometer of n-3 fatty acid consumption. The omega-3 index calculates the 436 
sum of n-3 fatty acids, usually the addition of levels of EPA and DHA, within the 437 
erythrocyte compartment, and has been substantiated as reflecting longer term intakes 438 
of dietary n-3 fat relative to other fatty acid species. Other instances of use of fatty acids 439 
in blood exist to quantitate the type of fatty acids consumed over the longer term. For 440 
instance, margaric acid levels have been utilized as a proxy for dairy fat consumption 441 
(42). However, logistics involved with blood sampling, handling and storage may limit 442 
the availability and/or choice of type of blood samples. In some cases, it may be 443 
possible to translate fatty acid data from one blood fraction to an equivalent in another 444 
blood fraction (43), for instance, measuring RBC fatty acids and estimating fasting 445 
plasma fatty acid levels. Any such translation, should be done with caution and 446 
appropriate caveats should be considered. Such monitoring is useful to assess 447 
adequacy of intakes particularly for essential fatty acids, and especially in low resource 448 
regions where essential fat intakes, including n-3 fatty acids, appear insufficient (5).  449 
Thus, considerable merit exists in identifying a suitable fatty acid blood compartment for 450 
assessment of nutritional status and or recent intake levels in cross sectional trials. One 451 
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important consideration in both cross-sectional and prospective studies is to consider 452 
the use of circulating fatty acid levels as surrogates for fat intakes, but in the context of 453 
the limitation of inter-individual variations. It has been shown that substantial variations 454 
exist not only in circulating fatty acid profiles across individuals, but also in the degree of 455 
responsiveness to dietary fat challenges across different persons. Some of this 456 
variability is random, but some can be ascribed to various factors including baseline 457 
dietary patterns (4). This includes lifestyle behaviors such as smoking, alcohol, physical 458 
activity (44-46) but also age (47), sex (48) and the increasingly recognized influence of 459 
genetics (49, 50). The role of genetic polymorphisms related to fatty acid 460 
interconversion, and ultimately levels in circulation, following dietary interventions has 461 
been demonstrated and is the focus of ongoing research (49-51).  For EPA+DHA blood 462 
levels, fish and fish oil consumption accounts for an estimated 47% of variability while 463 
other factors such as age and smoking account for approximately 10% of variability 464 
combined (44).  Analytical variation around EPA and DHA fatty acid measurements are 465 
generally below 5% coefficient of variation (52). 466 
Researchers should also be aware that biological ranges of fatty acids in the blood of 467 
humans have been established in many cases. These ranges should be used when 468 
interpreting the study results. For example, the ratio of EPA+DHA to total fatty acids 469 
ranges over approximately 1-15 in various blood pools from populations across the 470 
globe in a comprehensive literature review (5), which is similar to the range defined in 471 
erythrocytes of n=160,000 participants determined in a single analytical laboratory (53). 472 
Failure to consider known ranges of fatty acid intake or levels in specific pools in 473 
populations can lead to speculation contradicted by known disease risk or prevalence. 474 
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Recommendation   475 
9) Population and blood pool ranges. Levels of particular or summed fatty acids, such 476 
as n-3 fatty acids, are modified in specific populations and/or blood pools. These 477 
changes should be taken into account when interpreting the results. 478 
3.0 Sample collection procedures 479 
Many sample collection conditions can influence the blood fatty acid profile, including 480 
but not limited to fasting/postprandial status, variations related to sex (e.g. menstrual 481 
cycle timing), dynamic effects related to diagnosed medical condition or syndrome and 482 
corresponding treatment therapy, recent alcohol, tobacco and/or drug use, as well as 483 
the blood sampling protocol itself (e.g. use of anticoagulants, use of antioxidants, length 484 
of handling time, etc.). Details of sample storage and archiving including timing, 485 
freezing, and storage temperatures should be reported. Special attention should be 486 
given to conditions that may cause PUFA oxidation including the use of antioxidants 487 
and iron chelators intended to minimize oxidation risk. Storage temperatures, freeze-488 
thaw cycles, and oxygen exposure all may increase oxidation risk. Numerous control 489 
points require special attention to ensure sample collection that minimizes alterations in 490 
the fatty acid profile during storage.  491 
3.1 Participant metabolic state 492 
In response to food intake, marked fatty acids shifts occur in the plasma. After food 493 
intake, the postprandial state is characterized by higher TG levels in the plasma. 494 
Moreover, the postprandial state is more variable than the morning fasting state from a 495 
metabolic point of view. Therefore, the postprandial stage is a transition stage and 496 
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samples collected in this period should be avoided unless the investigators are 497 
purposely evaluating the postprandial stage, or a blood fraction or fatty acid pool that is 498 
relatively stable fatty acid (e.g. PLs) in the postprandial state is to be examined. The 499 
postprandial rise in plasma fatty acids studied with and without stable isotope labels 500 
show that levels remain elevated even at 4-6 h after the meal (54, 55). To accurately 501 
monitor TG levels, a fasting duration of 9-16 h has been recommended, during which 502 
only water is permitted (56). In addition, alcohol should not be consumed for 24 h before 503 
blood sample collection because it can increase TG levels (56). The fasting period, 504 
typically overnight, should then be 10-12 h. In contrast, if fatty acid profiles are 505 
evaluated in RBC, strict guidelines for fasting may not be necessary. Also, certain fatty 506 
acids appear more resistant to postprandial effects. n-3 PUFA status can be accurately 507 
assessed in postprandial samples in whole blood, plasma or erythrocytes depending on 508 
how samples are analyzed and data are expressed. For instance, %omega-3 HUFA of 509 
total HUFA is more robust to transient changes in circulating postprandial fatty acids 510 
than other indexes or individual fatty acids as a percent or concentration of total fatty 511 
acids (57).  512 
Other conditions modifying blood lipid content in participants include: sex, age, diabetes 513 
or glucose intolerance, pregnancy or lactation, medication modifying blood lipid levels 514 
such as cholesterol or TG lowering drugs, obesity, athletics, or highly active participants 515 
(e.g. marathon runner), menopause, chronic or acute smoking (4, 44). For instance, 516 
smoking a single cigarette increases the metabolic rate of TG-rich lipoproteins (58).  517 
Recommendation 518 
  
 
26 
10) Relevant physiological state. Reports should outline medical, physiological and 519 
behavioral conditions that may influence fatty acid target outcomes and discuss steps 520 
taken to minimize their effects. 521 
3.2 Blood sample collection conditions 522 
Biochemistry parameters are generally derived from measurements of serum or plasma. 523 
Blood collection parameters such as participant posture, season of blood collection, and 524 
the duration of the tourniquet application can cause shifts in cholesterol and TG pools 525 
(59, 60). Plasma samples have several advantages over serum samples such as 526 
obtaining the samples faster since there is no waiting for blood clotting, shorter 527 
centrifugation time since centrifugation speed can be higher for plasma samples 528 
compared to serum samples (61). Plasma samples have been shown to have slightly 529 
lower concentrations of cholesterol than serum due to an osmotic effect of the 530 
anticoagulants extracting water from cellular contents (59). However, the fatty acid 531 
composition of serum and plasma has been shown to be remarkably similar when 532 
expressed as relative percentages of total fatty acids (62). The most popular vessels for 533 
collecting plasma are EDTA, heparin and citrate loaded tubes, and for collecting serum 534 
the most popular tubes are those coated with silica. Between blood sample collection 535 
and centrifugation, blood samples to be used for separating plasma from red cells 536 
should be kept on ice to avoid fatty acid hydrolysis from glycerolipids, a process that 537 
can result in artifactual change in the levels of NEFA or FFA and possibly PL and TG in 538 
the plasma.  539 
3.3 Sample Storage  540 
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Appropriate storage of plasma/blood samples collected during an RCT, a cross-541 
sectional or a prospective study is critical to preserve sample quality and to ensure an 542 
accurate measure of the fatty acid profile. Inappropriate storage conditions can lead to 543 
peroxidation of the fatty acids and the hydrolysis of fatty acids from PLs. In general, the 544 
presence of RBC in a sample can increase the risk of oxidation. The stability of blood 545 
fatty acids during storage and possible mechanisms of fatty acid degradation have been 546 
reviewed recently (15). In general, PUFA are susceptible to peroxidation due to the 547 
attack of free radicals. Free radical generation is increased with exposure to oxygen and 548 
the presence of iron (hemoglobin complex) in the samples. Peroxidation can be 549 
prevented or reduced through the addition of antioxidants (63), chelating and/or 550 
cryopreserving agents (17), as well as the presence other oxidizable compounds in the 551 
sample that may act as alternative targets such as vitamin E and various proteins (64, 552 
65). 553 
Samples should be stored at -80°C to prevent oxidation of plasma PL PUFA. This 554 
temperature prevents degradation of long chain PUFA in the PL fraction serum pool for 555 
at least 10 years (66). The fatty acid composition of plasma PLs is also stable for at 556 
least one year when stored at -20°C (67, 68). Surprisingly, there are no studies that 557 
evaluate stability of the fatty acid profile in plasma total lipid extracts. Therefore, it is 558 
difficult to make any recommendation with respect to number of years and storage 559 
temperature. However, Matthan et al. performed fatty acid profile analyses in TG, PL 560 
and CE in samples stored at -80°C and found that fatty acid profile was stable for > 10 561 
years (66). Another group also analyzed the fatty acid profile in TG, PL and CE in 562 
plasma samples stored at -20°C for 3 years and they determined that PUFA were stable 563 
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for < 3 years. Considering these caveats and because there are no data per se on the 564 
stability of fatty acids in plasma total lipids, fatty acids in plasma total lipid extract is 565 
considered stable for at least 10 years if stored at -80°C but stability is < 3 years if 566 
stored at -20°C. Plasma FFA are known to increase when stored at -20°C or above as 567 
these temperatures do not appear to be cold enough to prevent phospholipase activity 568 
(69-71). 569 
Compared to plasma fatty acid stability lasting for more than 10 years if stored at -80°C, 570 
RBC fatty acid stability is lower because RBC iron, when released, catalyzes long chain 571 
PUFA oxidation (17). Therefore, specific considerations require attention when dealing 572 
with this lipid pool. For instance fatty acids from RBC total lipids that were stored at -573 
20°C without any specific storage additive such as N2 or BHT were stable for 13 d to 574 
less than 6 mo. (63, 72, 73). Fatty acid stability was highly improved when RBC were 575 
stored at -70°C without any added antioxidant agents (74). One study showed that fatty 576 
acids in RBC phosphatidylcholine were stable more than 2 years if RBC were stored at -577 
80°C (47). Studies using unwashed erythrocytes yielded results similar to studies that 578 
washed erythrocytes prior to storage (15).  To maintain stability of RBC, investigators 579 
should consider adding antioxidant such as BHT to stabilize RBC containing samples. 580 
Therefore, storage temperature seems critical, especially for RBC, for maintaining 581 
sample quality with respect to fatty acid content and prevention of oxidation. Storage 582 
also depends on format, with vials limiting oxygen exposure more reliable than paper; 583 
details are available (75). Storage for weeks at  -20°C (63) should be avoided for 584 
erythrocyte-containing samples to avoid iron release through hemolysis (17) as samples 585 
stored at room temperature or 4°C are more stable.  586 
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Whole blood samples appear to be the less stable than plasma and RBC samples (15). 587 
The increased risk of PUFA losses in whole blood appears to be due to water content in 588 
the samples as RBC diluted in saline are less stable than packed RBC samples, (15) 589 
suggesting higher water content may increase the amount of freezing-induced 590 
hemolysis, which releases iron. Freezing-induced hemolysis appears to be responsible 591 
for the rapid decline in PUFA in whole blood and RBC samples when they are stored at 592 
-20°C (17), as samples stored at room temperature and 4°C are more stable (75). 593 
Freezing-induced hemolysis also occurs at -80°C, but PUFA levels are relatively stable 594 
when contrasted with -20°C storage. It appears that -20°C storage is not sufficiently cold 595 
to prevent oxidative processes, as BHT can prevent much PUFA loss at -20°C (75). 596 
Cryopreservatives that protect against hemolysis and chelators that bind iron prevent 597 
PUFA losses at -20°C, but BHT appears to be the most effective single treatment (75). 598 
For whole blood stored as dried blood spots, the risk of oxidation is increased compared 599 
to storage in tubes as dried blood spots are exposed to atmospheric oxygen. Drying the 600 
blood spot thoroughly before low temperature storage can prevent hemolysis and 601 
increase stability. However, BHT and/or other protective agents should be considered 602 
as they can extend PUFA stability in DBS under various conditions (15) including room 603 
temperature storage (76). 604 
Other storage conditions that should also be considered include the size of the aliquot 605 
to be stored and freeze /thaw cycling. Smaller aliquots of samples have a greater 606 
surface area to volume ratio as compared with larger aliquots, which increases the 607 
exposure to oxygen and results in more degradation (72). Freeze/thaw cycling of 608 
samples is largely believed to be detrimental, but this appears to be based on studies 609 
  
 
30 
employing enzymatic assays to examine various clinical blood lipid classes such as 610 
cholesterol and TG and the findings are not consistent (77). Limited research exists 611 
probing effects of freeze-thaw with subsequent fatty acid determinations by gas 612 
chromatography (GC); one of the few studies suggested that repeated freeze/thaw 613 
cycling had limited impact on lipid concentrations, including fatty acids, in unfractionated 614 
serum (77). However, sample handling should limit freeze/thaw and minimize the time a 615 
sample spends at temperatures above ultra-cold temperatures (less than -50 C). 616 
Reference should be made to validation that the key fatty acids or indexes (e.g. 617 
%HUFA) are preserved under the conditions of storage. 618 
Recommendation  619 
11) Sample integrity during storage. Details of sampling and storage should be 620 
reported, including timing between sampling and analysis, storage temperature, 621 
duration, and any antioxidant/protectant used.  622 
4.0 Sample preparation and analysis 623 
4.1 Lipid extraction 624 
Methods of preparing samples for fatty acid analysis require a validation study prior to 625 
use. Traditionally, lipids were first extracted from a sample and then derivatized to fatty 626 
acid methyl esters (FAME) for improved response in a gas chromatograph (12). Lipid 627 
extraction can be tailored to sample type but for blood samples, lipid extraction 628 
techniques that extract polar and nonpolar lipids such as Folch (78) and for samples 629 
with low lipid content, Bligh & Dyer (79) are common. Techniques designed to extract 630 
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nonpolar lipids such as those used to monitor the food supply should be avoided or 631 
used with caution (18).  632 
4.2 Derivatization of fatty acids  633 
This sample preparation step typically requires some form of hydrolysis or 634 
transesterification of the fatty acids from complex lipids. While saponification with a 635 
strong base prior to esterification was once common, several transesterification 636 
protocols have been developed where the fatty acid methyl ester is formed during 637 
hydrolysis from the complex lipid. Base-catalyzed methylation procedures are not 638 
suitable for esterification of NEFA or transesterification of amide linkages found in 639 
sphingolipids. Acid catalysis can drive esterification and transesterification reactions. 640 
While methanolic HCl and sulfuric acid in methanol can be used, the much harsher BF3 641 
in methanol is commonly employed to speed up the reaction despite the increased 642 
potential for artifact generation. In addition, various one-step extraction and 643 
derivatization techniques such as Lepage & Roy and others (80-82) and no extraction, 644 
direction transesterification methods have often been utilized. In general, all chemical 645 
methods are specific to analyte and to the chemical matrix. For example, water content 646 
can be critical in direct transesterification methods (83). Therefore, methods developed 647 
for fatty acids in one sample matrix (e.g. RBC) are not applicable to fatty acids in 648 
another matrix (e.g. milk) without a specific validation study. Validation studies for the 649 
specific methods mentioned develop a set of chemical principles and report optimized 650 
parameters. Laboratories using any method should use proper quality control 651 
techniques upon first use to establish routine protocols on surplus samples prior to use 652 
of study samples. Applying an established method to a new sample matrix requires 653 
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side-by-side, replicate preparation with an extensive set of internal standards to 654 
compare accuracy and precision of the putative method with the established method. 655 
Specific principles are usually relevant to particular methods. For instance, the Bligh 656 
and Dyer method requires a ternary mixture of chloroform, methanol, and water to 657 
achieve a single phase and highly effective extraction. Failure to achieve a single phase 658 
because of excess water in the sample causes the method to be very inefficient.  659 
Recommendation  660 
12) Fit-for-purpose sample preparation. Method used to extract fatty acids and 661 
derivatize fatty acids to FAME should be explicitly stated and reference to the original 662 
studies of their use be cited.  663 
4.3 FAME Analysis 664 
As noted above, the biomedical literature overwhelmingly uses the term fatty acids to 665 
refer to fatty acyl species as well as NEFA (FFA), as a shorthand nomenclature to refer 666 
to all fatty acids liberated as a result of an acid or base lipolysis of a biological 667 
sample.(3) Typically fatty acids will be converted to their FAME derivatives for analytical 668 
purposes.   669 
The classic and most widely used method for FAME analysis is GC coupled to either a 670 
flame ionization detector or an electron ionization (formerly known as electron impact, 671 
EI) ion source mass spectrometer (GC/MS). FID inherently produces signal 672 
approximately on a per mg basis whereas GC/MS produces signal on a per mole basis. 673 
Importantly, FID does not yield information on chemical structure. GC/MS yield 674 
structural information such as molecular mass (weight) but for FAME cannot locate 675 
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double bond position (84) and in many cases is ambiguous with respect to chain 676 
branching (85). 677 
Electrospray MS/MS via LC/MS/MS or shotgun methods are not preferred for fatty acid 678 
analysis because these approaches are not as specific or broadly applicable for fatty 679 
acids as GC. Because of chemical properties of aliphatic hydrocarbon chains in mass 680 
spectrometers, double bond position and geometry (cis-trans), and chain branching, are 681 
seldom captured in conventional LC/MS/MS analyses. Carbon and double bond 682 
numbers typically can consist of dozens of possible isomers and require information 683 
external to the sample to assign them to a structure (e.g. 22:6 is usually all-cis-684 
4,7,10,13,16,19-docosahexaenoic acid). Moreover, LC/MS/MS generally requires 685 
isotopically labeled internal standards to enable acceptable quantitative analysis. 686 
Analysis over a range of two dozen fatty acid features requires a similar set of 687 
isotopically labeled internal samples, which is seldom available.  688 
Recommendation   689 
13) Analytical chemical fidelity. Methods should be reported in sufficient detail to 690 
establish unequivocally fatty acid identity and resolution. 691 
5.0 Reporting 692 
5.1 Relative versus absolute concentrations 693 
Fatty acid are reported in two formats, relative and absolute. 694 
Relative. Known as fatty acid profiling, the units are expressed as percent by weight of 695 
total fatty acids, also known as weight-for-weight and abbreviated variously as “%, w/w” 696 
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or “g/100g”. Profile reporting is the most common means of expressing fatty acid data 697 
(5). Weight is the natural unit for a GC-FID analysis because the FID responds to the 698 
total C and H burned rather than the moles of each analyte eluting from the column. 699 
Importantly, this method also is natural for studies focused on competition between 700 
various fatty acids for access to metabolism such as transport proteins, esterification, 701 
and interconversion from one fatty acid to another.  702 
Profile percentages tend to exhibit lower variability than absolute concentration 703 
(discussed below) and tend to be distributed normally, a statistical advantage. As a 704 
result, proposed blood biomarkers of n-3 PUFA status are typically relative percentages 705 
or ratios (14, 62, 86); concentrations of n-3 PUFA without context are difficult to interpret 706 
because high concentrations could be a result of general lipemia rather than a specific 707 
increase in n-3 PUFA. A recent systematic review of the blood fatty acid data of healthy 708 
adults across the globe revealed that 78% of the data were reported as weight % overall 709 
with higher reporting percentages in the erythrocyte (91%), whole blood (92%), and 710 
plasma PL (83%) blood fractions.(5) 711 
Absolute. Expressing fatty acid concentrations in terms of concentration in a fluid (e.g. 712 
plasma) or tissue, for instance, as milligrams fatty acids per milliliter plasma is 713 
appropriate when the goal is to establish the total available fatty acids. Importantly, in 714 
most biological systems, lipids are not dissolved but are maintained in suspension in 715 
various ways, as cells (e.g. RBC), lipoproteins, or bound to transport proteins. 716 
Dissolution in aqueous solution implies a molecular dispersion, useful as a proxy for 717 
collision frequency that enters into reaction rate definition. Lipids in suspension are not 718 
molecular dispersions, and in their native environment where biology occurs, (e.g. a 719 
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membrane or the core of a lipoprotein particle) they are at far higher concentration than 720 
in the bulk fluid or tissue. The concept of absolute concentration must therefore be 721 
understood as defining an average mass per unit fluid or tissue. Methods for measuring 722 
concentration do not inherently depend on measurement of a range of fatty acids but 723 
can be restricted to as few as one FA.  724 
Absolute fatty acid concentrations tend to result in greater intersubject variability and is 725 
prone to multimodal distributions in blood and other tissues and fluids. In these cases, 726 
statistical analyses can be limited to nonparametric approaches or data require 727 
transformation.  728 
Both relative and absolute fatty acid measures are used for expressing fatty acid 729 
concentrations depending on the nature of the specific issue considered. The choice of 730 
units influences the magnitude of apparent changes (87) and can yield an apparent 731 
contradiction in final conclusions (88, 89). Of the many considerations involved in 732 
formulating a critical hypothesis at the heart of competing theories in equipoise and 733 
designing a study to provide an unambiguous confirmation or refutation of the 734 
hypothesis, is the units for expressing outcomes. The hypothesis and research 735 
questions in fatty acid studies should be formulated in sufficient detail to specify which 736 
units are relevant. 737 
Recommendation   738 
14) Fatty acid units. The rationale for primary reporting of fatty acid profile or absolute 739 
fatty acid concentration should be reported with respect to the hypotheses. 740 
Combined with an independent measure of total fatty acids per unit fluid (e.g. milliliter 741 
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plasma) or tissue (e.g. g muscle), all fatty acids can be converted to absolute 742 
concentration units. Percent of total fatty acids normalizes to the total fat amount, 743 
which is often reflective of sampling (e.g. volume of plasma, number of cells) in a 744 
manner similar to normalization to protein for other analytes. Fatty acid profiling does 745 
not capture changes in the total fatty acid pool, for instance, when lipemia increases 746 
total fatty acids per unit plasma. Decreases in a particular target fatty acid can be 747 
misleading under these circumstances when, for instance, the total fatty acid 748 
concentration increases but a target fatty acid decreases as a percentage of total. As 749 
an example, long chain PUFA as a percent of total fatty acids tend to be at higher 750 
concentration in plasma PL than in plasma TG.(5, 90) Postprandial lipemia consisting 751 
primarily of TG dramatically increases plasma total fat, reducing the percent of PUFA 752 
as a profile percentage but not reducing their concentration expressed as mg/dl 753 
plasma. 754 
Recommendation   755 
15) Data interconvertibility. Regardless of the choice of primary reporting method, all 756 
reports should include sufficient data to convert relative to absolute concentrations 757 
and vice versa. 758 
5.2 Calculating Total Fatty acids for Profiles 759 
Surprisingly, no standardized list of fatty acids to be included in a “total fatty acids” sum 760 
is in use or to our knowledge, proposed. The total fatty acids reported has largely been 761 
an arbitrary decision of the researcher and is seldom justified in reports. Concerns 762 
about concise reporting have led to pressure from journal editors for truncated fatty acid 763 
  
 
37 
composition tables, especially in the pre-web era prior to the advent of supplementary 764 
data.  765 
The recent systematic review of blood fatty acid composition of healthy adults across 766 
the globe (5) shows that 9.4 ± 5.8 fatty acids are reported. Surprisingly, over 30% of the 767 
studies reported 5 or less fatty acids, with 2% of the studies reporting no individual fatty 768 
acids, but only composite scores (e.g. n-3 EPA+DHA). This variation in reporting is 769 
remarkable, particularly considering that the data were all generated by nominally 770 
similar analytical procedures – GC with a capillary column. 771 
The fewer the fatty acids that are summed, the greater the apparent profile percentage 772 
of those reported. Researchers have employed two approaches for choosing fatty acids: 773 
1) summing the total of identified fatty acids, and 2) summing the total of unidentified 774 
fatty acids. For the “identified fatty acids” approach, fewer fatty acids are typically 775 
summed inflating the relative percentage of fatty acids reported. For the “unidentified 776 
fatty acids” approach, it is important to establish that the unidentified peaks are in fact, 777 
fatty acids and not other lipids or contaminants such as cholesterol (91), phthalates 778 
(92), or butylated hydroxytoluene breakdown products (93). Either approach may 779 
depend on methodological details such as type of capillary column (94), or technique 780 
used to prepare FAME (62). 781 
In 2012, the NIST along with the Centers for Disease Control and Prevention (CDC) and 782 
NIH’s Office of Dietary Supplements (ODS) initiated the fatty acid quality assurance 783 
program (FAQAP) to promote clinical comparability of analytical results (52), followed 784 
up by a second and third exercises in 2015 (95) and 2016 (96) using a procedure 785 
generally referred to as a “round robin” or “ring test”. Several laboratories around the 786 
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world received standard reference materials (SRM) generated by NIST consisting of 787 
serum for fatty acid analysis. In the initial exercise, a preliminary list of 24 fatty acids 788 
was requested, although participants were asked to include any fatty acids that they 789 
typically report. The % of participating labs reporting each of these 24 fatty acids varied 790 
from 100% for 20:4n-6, 20:5n-3 and 22:6n-3 in all three exercises to 64%, 50% and 791 
33% for 22:1n-9 in exercise 1, 2 and 3, respectively (Supplemental Table 1). The 792 
reduced percentages in reporting of common fatty acids in exercise 2 and 3 were due to 793 
the inclusion of a laboratory using targeted HPLC measurements, rather than 794 
comprehensive GC profiling. In addition, for exercises 2 and 3, participants were 795 
encouraged to include measurements of additional fatty acids, but the percentages of 796 
labs reporting any of these additional fatty acids were all below 50% (Supplemental 797 
Table 2). As the FAQAP examined only serum, the reporting practices for fatty acids 798 
across blood fractions was examined in the global map database (5). The percentage of 799 
studies reporting mean relative % values of the 24 individual fatty acids identified by 800 
NIST were examined for the fatty acid compositions of 359 separate reports that 801 
presented data as relative % (Supplemental Table 3). The frequency of reporting for 802 
22:1n-9 and 14:1n-5 was quite low (below 10% in all blood fractions). The mean relative 803 
% contribution of 14:1n-5 was below 0.04% for all blood fractions while for 22:1n-9 it 804 
was 1.00% in plasma PL.  805 
The number of fatty acids that can be identified and quantified is dictated in part by 806 
capillary column choice.  The use of a traditional polyethylene glycol capillary column 807 
and a biscyanopropyl column marketed for trans fatty acid determinations for plasma 808 
profiling serves as an example (Table 1). The biscyanopropyl column enabled the 809 
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quantification of 12 additional minor fatty acids (% contributions <0.15%). Based on 810 
reporting practices and relative % contribution to the total fatty acids, this working group 811 
categorized the fatty acids into categories primarily based on arbitrary abundance 812 
ranges (Table 1). The A category includes fatty acids with abundances greater than 813 
0.30% of total fatty acids with some fatty acids known to be critical for interpreting 814 
metabolism (e.g. see Mead acid below). This list has 21 fatty acids of which the sum is 815 
≥95% of the total plasma fatty acids. To our knowledge, no external standard mixture 816 
currently exists with all 21 “A” fatty acids listed in Table 1. The B category includes 817 
seven fatty acids with abundances typically between 0.10-0.30% of total fatty acids that 818 
can be detected on a general Carbowax column but may vary across blood pools. 819 
Finally, the C category included fatty acids below 0.20% of total and required high 820 
polarity columns for detection. While as many fatty acids as possible should be included 821 
in calculations of “total fatty acids”, it is important that the fatty acids in category A are 822 
reported to improve the consistency of relative % data.  Any exceptions should be 823 
noted. For example, Mead acid (20:3n-9) is important in assessing essential fatty acid 824 
status and should be reported. If below limits of detection/quantitation as common in 825 
populations with contemporary high dietary intakes of PUFA such as 18:2n-6, it should 826 
be reported as such.  Category B and C fatty acids will be important to specific cases 827 
and should be reported when relevant. 828 
The sum of the fatty acids in various blood fraction profiles should reflect ≥95% of the 829 
total plasma fatty acids at minimum with >97% being desirable. Considering the mean 830 
number of reported fatty acids noted above, 9.4 ± 5.8, would not fit this criterion. 831 
Recognizing that an increase in many fatty acids of 10% is biologically important, the 832 
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choice of base is clearly important for any particular study. Moreover, systematic 833 
reviews and meta-analyses would suffer substantial increases to uncertainty that would 834 
bias toward the null result solely based on non-standardized analysis. Additional fatty 835 
acids may need to be identified for other human tissue pools (e.g. skin) or foods.  836 
Recommendation   837 
16) Fatty acid base. The base of total fatty acids used in profile calculations should 838 
be specified, and the range of fatty acids marked in Table 1, particularly those in 839 
Category A should be reported to enable secondary calculations and interpretation. 840 
5.3 Analytical chemical considerations 841 
5.3.1 Response Factors by Equal Weight External Standard 842 
Fatty acid profiles are panels of fatty acid measurements. Each measured fatty acid is 843 
an integrated peak area that must be calibrated in some way to yield interpretable 844 
results. The classic method for calibration is via response factors (97). Responses vary 845 
depending on instrument settings. In a classical GC with a flame ionization detector 846 
(GC-FID), the major variation is in the injector due to differential loading of FAME onto 847 
the capillary column during split injection (98), with the detector responding similarly to 848 
each fatty acid according to its carbon and hydrogen content. Response factors are 849 
determined by preparing an external standard mixture of FAME all at equal weight, or 850 
known unequal weight, and applying a correction to the raw areas based on differential 851 
response. Typically, a single fatty acid of strong intensity in the external standard and 852 
the samples, such as 16:0, will be chosen as a base. Alternatively, the instrument 853 
settings can be adjusted to yield equal raw areas across the range of relevant fatty 854 
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acids, so that no correction is needed later. Area percents are raw data and are in 855 
general biased measures unless calibrated, and should not be reported as 856 
representative of fatty acid abundances (98). 857 
For GC/MS, response factors are particularly critical because the response depends on 858 
the ionization and fragmentation behavior of each FAME and the ions chosen to 859 
quantify FAME. As a general rule, GC/MS is not recommended for quantitative analysis 860 
because the FID is a more stable and more linear detector. 861 
Recommendation  862 
17) Relative response calibration. In practice, response factors should be evaluated 863 
daily. 864 
5.3.2 Internal standards (IS) 865 
Internal standards are added quantitatively to a sample mixture to calibrate signal at the 866 
step where addition occurs and for all subsequent steps. Their advantage is that they 867 
parallel the chemistry of the analyte, including losses, during all protocol steps. For 868 
water soluble analytes, methods have been established for treating internal standards 869 
(IS) (99). However, for lipid analyses in biological mixtures, more than one phase is 870 
present in starting materials, thus the concentration of the IS is an unknown partitioned 871 
among the phases. Therefore, IS are not appropriate until lipid is extracted into a single 872 
phase unless the partitioning behavior of the IS in the specific protocol has been 873 
specifically examined. IS can be added when there is one phase in an extract mixture, 874 
such as the single phase water:methanol:chloroform mixture of the Bligh & Dyer method 875 
(79) to evaluate extraction and instrument response. The standard should be a fatty 876 
  
 
42 
acid that is reliably found at negligible levels in the sample, appears at a retention time 877 
that is free of interferences, is added at a concentration to provide a peak height within 878 
the range of fatty acids to be calibrated, such as 5% of total fatty acids or a ratio of 1 to 879 
20, and may be added as a target lipid class, (e.g. di-acyl phosphatidylcholine) of 880 
interest to accurately track the behavior of the target analyte. If mass spectrometry is 881 
used, then an isotopically labeled species is appropriate, or possibly GC can be used to 882 
isolate deuterated FAME chromatographically. Depending on target fatty acids and the 883 
questions being addressed, it is not always possible or desirable to add IS and fatty acid 884 
profile can stand on its own.  885 
When appropriate, IS should be added quantitatively so to be able to derive a 886 
calibration factor in the units of concentration per count, for instance milligrams fatty 887 
acids per milliliter of FAME mixture per raw data count. These can then be applied to 888 
calibrated profile area percents to determine concentrations of all FAME in the 889 
extraction mixture. Conversion factors to the sample sizes (e.g. milliliters) and 890 
customary units (mg fatty acids / deciliter plasma) yield the final results. 891 
IS are not needed for all studies. Cases of complex FAME mixtures where there is no 892 
flat baseline to include IS, or those in which only fatty acid profiles are desired, need no 893 
IS, though all require response calibration from an external standard.  894 
Recommendation   895 
18) Internal standards. Rationale and procedure for IS should be reported, when 896 
used. 897 
5.3.3 FAME separation and identification 898 
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Baseline separation is recognized as ideal for quantitative analysis; however, this is not 899 
possible when a  large number of analytes exist in a complex mixture (100). GC 900 
parameters should be adjusted to enable baseline separation of target peaks, 901 
particularly those of low relative abundance, as well as symmetric peak shapes to 902 
enable accurate and precise area integration by conventional techniques. 903 
Positive identification of FAME including double bond position and geometry, and chain 904 
branching, that excludes all but one correct structure generally requires higher end 905 
equipment and methods than are available in most labs or can be justified for all 906 
samples. At a minimum, retention times and molecular weights should match those of 907 
genuine standards. Laboratories that do not have advanced methods should carefully 908 
adhere to sample types with a known pattern of FAME, for instance the various blood 909 
lipid or lipoprotein groups or cell types. Non-FAME compounds eluting in FAME 910 
analyses include plasticizers, antioxidants and their reaction products, and peaks 911 
originating from unknown sources. All unknown peaks appearing in one or more 912 
chromatograms in a series should be evaluated as to whether they are FAME or not. 913 
Methods for estimating retention times such as Kovats retention indexes can be 914 
executed without access to mass spectrometry. 915 
Recommendation   916 
19) Fatty acid identity. The identity of all FAME must be established for accurate 917 
analysis, and methods reported in the paper or supplementary materials.  918 
5.3.4 LC/MS 919 
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LC/MS/MS is the standard method for pharmaceutical analyses of drugs and 920 
metabolites. Recommendation for methodology for method validation and quality control 921 
is long established (99). The rise of ‘omics techniques and especially targeted analyte 922 
panels is analogous to the fatty acid profile used for decades by GC (3). Generally, high 923 
performance methods are needed to provide similar specificity of qualitative analysis for 924 
structure, separation power, and quantitative analysis, compared to high resolution GC. 925 
LC/MS can also be used for analysis of intact glycerolipids, but is not recommended as 926 
a method to assess overall fatty acid profile because of difficulties calibrating the vast 927 
number of chemically distinct species in a single biological sample. Hydrolyzed fatty 928 
acid LC analysis is analogous to FAME analysis by GC.  929 
Recommendation   930 
20) Comprehensive analysis. When LC/MS is necessary, panels of fatty acids 931 
encompassing at least the same range that are routine in GC should be analyzed 932 
qualitatively and quantitatively.  933 
5.3.5 Method validation & Quality control 934 
The validation and quality control for laboratory fatty acid measurements may be 935 
established in part to be consistent with the validation principles for drug as stated in 936 
Bioanalytical Method Validation in Guidance for Industry by FDA (101) and reported by 937 
Shah et al. (99). Analytical figure-of-merit include intra-day and inter-day precision, 938 
accuracy, linearity range, and should be established by appropriate working standards. 939 
Validation should be conducted when fatty acid analyses are new to a laboratory or 940 
when a method is modified in either chemical procedure such as high throughput assay, 941 
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microwave irradiation or instrumental parameters such as fast GC, and or use of high-942 
efficiency columns.  943 
For assessment of accuracy, the results from the repeated measurements of same 944 
sample by the new lab or the new method will be compared to those by an established 945 
lab or one of the conventional methods: (e.g. Folch, Bligh & Dyer, Lepage and Roy).  946 
Precision of concentration measurements (e.g. mg fatty acids per ml plasma) is 947 
acceptable at the ±15% CV level through the linear range and it is accepted for a range 948 
and ± 20% at the lowest level of quantification, as recommended for conventional 949 
measurements by Shah et al. (99). Precision for data expressed as %wt should be 950 
considerably improved compared to these criteria1, with major peaks (>3% of total fatty 951 
acids) having CV < 5%. Precision for minor peaks is poorer and depends on the peak 952 
abundance. Precision and accuracy must be fit-for-purpose, where the hypothesis is 953 
stated a priori as a part of the study aims and will often be addressed implicitly in a 954 
power calculation. A reasonable reference point is the biological variability of the 955 
specific fatty acids in the population under study or the closest population for which data 956 
are available. For instance, the test-retest SD should be lower than the SD of the 957 
population. 958 
Precision and lower limits of quantification (LLOQ) are always a function of signal 959 
intensity. When injected masses or concentrations (depending on technique) are 960 
unnecessarily low, precision is unnecessarily low and minor peaks can fall below 961 
quantifiable limits. Undetected fatty acids pose statistical dilemmas as their treatment as 962 
                                               
1
 The descriptive word “improved” or “poorer” is used to refer to precision, rather than “lower precision” 
which can be confused with a smaller SD, for instance. 
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missing values, or as zero, influences the outcome of statistical analysis (87). Care 963 
should be taken to insure that all relevant peaks are on scale. Linearity should be 964 
established for specific instruments. A common solution to limited linear dynamic range 965 
is to inject samples at differing concentrations or quantities and bridge data in the two 966 
chromatograms using intermediate intensity peaks that are on scale in both injections. 967 
Most reports record “not detected” or “trace” to reflect no signal or signal below 968 
quantifiable limits, respectively. Far more useful is to estimate by similar detected or 969 
quantified signals the ability of the protocol, including important but unreported details 970 
like injected quantity and concentration, to detect particular low level fatty acids. 971 
Recommendation  972 
21) Minimal detectable limits. Limits of detection or lower limits of quantification 973 
should be reported when fatty acids are not detected/quantified. 974 
Quality control should be conducted routinely for both chemical procedures and 975 
instrumental performance in all labs. One recommended QC standard sample is the 976 
certified NIST SRMs for fatty acid measurement containing high, mid, and low 977 
concentrations of fatty acids. Others can be laboratory working standards containing 978 
fatty acids within a close range of those in samples of interest. The frequency of QC test 979 
for fatty acid measurement will depend on the number of samples, such as adding one 980 
QC sample every 100 samples or one for each batch of high throughput fatty acid 981 
assay. A QC test for instrument performance can apply the reference standard, either 982 
as single fatty acids or a mixture of fatty acids of known weights for checking the 983 
retention time, resolution of peaks, and response factors. The frequency of this QC test 984 
should be on a regular basis (e.g. once every week or every 100 samples).  985 
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Laboratories are encouraged to participate in a quality assurance program such as the 986 
NIST/NIH fatty acid Quality Assurance Program on a regular basis, such as once every 987 
six years.  988 
Recommendation  989 
22) Quality Control. Reports should specify QC procedures used for sample 990 
analyses. 991 
6.0 Conclusions 992 
Though fatty acid studies are among the most common in nutrition and biomedicine, 993 
their translation into recommendations is limited by heterogeneity and limited 994 
comparability due to differences between studies in design, analysis, reporting, and 995 
interpretation. The contemporary trend of combining studies in systematic reviews and 996 
meta-analyses tends to include all studies fitting particular criteria. However, such 997 
reviews often only refer to outlines of published details. Peer reviewed primary reports 998 
of clinical studies are more thorough in their vetting and reporting of statistics than in the 999 
many details specific to fatty acid metabolism and analysis. Careful attention to the 1000 
many known details is expected to improve accuracy and precision of results from study 1001 
to study.  1002 
In the 1950s, the eminent chemist Irving Langmuir described a hallmark of scientific 1003 
inquiry: As measurements are refined, the signal rises out of the noise (102). The 1004 
converse is also true, that failure to carefully control known sources of random and 1005 
systematic noise – unrefined measurements – swamps signals. In the case of fatty acid 1006 
studies, those signals are biomarkers and health outcomes.  1007 
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6.1 A Checklist.  1008 
We offer in Table 2 collected recommendations from this document that can serve study 1009 
designers, principal investigators, researchers, reviewers and readers. It is intended to 1010 
serve as a checklist for publication of fatty acid studies on a clinical and an experimental 1011 
basis.  1012 
As importantly, this set of recommendations may be considered a template for 1013 
analogous studies in the contemporary ‘omics’ fields in which large panels of analytes 1014 
or analytical features are intended as indicators of phenotype. Fatty acid panels are 1015 
among the first routinely measured and reported big data panels, with hundreds of 1016 
studies published by 1960 (3) and at a pace accelerating through the years. The 1017 
refinements of careful researchers over the decades should be built upon to enable 1018 
resolution of modern issues in the health sciences.  1019 
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Table 1. Fatty acids identified
1
 in SRM-2378-1 using various GC columns 
 
Inclusion 
category
2
 
Polyethylene glycol  
(DB-FFAP) 
Biscyanopropyl 
(SP-2560) 
12:0 B 0.22 0.18 
14:0 A 1.44 1.59 
15:0 B 0.15 0.19 
16:0 A 23.78 23.25 
17:0 B 0.25 0.27 
18:0 A 7.25 7.62 
20:0 B 0.16 0.20 
22:0 A 0.34 0.46 
23:0 B 0.12 0.19 
24:0 A 0.32 0.48 
12:1 C 0.01 0.01 
14:1 C 0.08 0.08 
16:1n-7 A 1.59 1.58 
18:1n-7 A
3
 1.50 1.38 
18:1n-9 A 17.14 17.28 
20:1n-9 B 0.13 0.16 
22:1n-9 B
5 
0.05 0.07 
24:1n-9 A 0.51 0.72 
20:3n-9 A
4
 0.05 0.05 
18:2n-6 A 27.93 28.65 
18:3n-6 A 0.33 0.37 
20:2n-6 A
4
 0.14 0.25 
20:3n-6 A 0.86 0.97 
20:4n-6 A 5.24 5.68 
22:2n-6 C 0.04 0.08 
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22:4n-6 A
4
 0.11 0.14 
22:5n-6 A
4
 0.08 0.12 
18:3n-3 A 0.82 0.88 
20:3n-3 C 0.04 0.02 
20:5n-3 A 2.18 2.52 
22:5n-3 A 0.59 0.65 
22:6n-3 A 2.59 2.80 
16:1t9 C 
 
0.01 
18:1t6-8 C 
 
0.04 
18:1t9 C 
 
0.10 
18:1t10 C 
 
0.11 
18:1t11 C 
 
0.11 
18:1t12 C 
 
0.08 
18:1t13 C 
 
0.16 
18:1c12 C 
 
0.11 
18:1c16 C 
 
0.09 
18:2c9t12 C 
 
0.11 
18:2t9c12 C 
 
0.05 
18:2c9t11 CLA C  0.05 
1
Data presented as relative percentages of total fatty acids (%,w/w).  
2
Category definitions are: A, abundance over 0.30% of total or if below of important physiological 
relevance; B, Abundance between 0.10 and 0.30% and detectable on a general Carbowax capillary GC 
column; C, low abundant fatty acids typically requiring high polarity GC columns for detection. 
3
18:1n-7 can co-elute with 18:1n-9 with certain GC-FID conditions and therefore should be reported as 
18:1 to indicate a summation. 
4
Fatty acid included in “A” category based on physiological relevance rather than abundance. 
5
Fatty acid included in “B” category based on abundance in RBC  
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Table 2. Checklist of Recommendations. Fatty Acid Best practices (FABP) organized in order 
of appearance under major headings in the text.  
Fatty acid trials. The independent variable. 
1) Treatment fatty acids. All fatty acids in the food or supplements relevant to the issue 
under investigation must be analyzed and defined. 
2) Sampled pool. Rationale for the choice of blood pool should be stated and justified 
with respect to biological research question, taking into account logistical issues with 
respect to study design. 
3) Intervention length. Intervention length should be rationalized based on the 
hypothesis.  
4) Control composition. Control (comparator/placebo) doses should be chosen to be 
neutral with respect to the outcome, considering the known metabolism and levels of 
dietary fat with respect to the hypothesis and the study population.  
5) Biological responsiveness. The responsiveness of the target fatty acid pools should 
be considered with respect to the chosen intervention doses and duration. 
6) Fatty acid dynamics. Dietary fatty acid exposure and implications for well-
established principles of fatty acid metabolism must be taken into account for 
interpreting the diet-blood relationship.  
7) Data analysis principles. All fatty acid intervention trials should report at least one 
measure of fatty acid concentration within a specified biological compartment so as 
to enable analysis on both an ITT and a PP basis. 
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8) Fatty acid ranges. Intervention-based changes in circulating fatty acids should be 
compared with previous literature reports to establish that they fall into expected 
ranges.  
Sample collection procedures 
9) Population and blood pool ranges. Levels of particular or summed fatty acids, such 
as n-3 fatty acids, are modified in specific populations and/or blood pools. These 
changes should be taken into account when interpreting the results.  
10) Relevant physiological state. Reports should outline medical, physiological and 
behavioral conditions that may influence fatty acid target outcomes and discuss 
steps taken to minimize their effects. 
Sample preparation and analysis 
11) Sample integrity during storage. Details of sampling and storage should be reported, 
including timing between sampling and analysis, storage temperature, duration, and 
any antioxidant/protectant used. 
12) Fit-for-purpose sample preparation. Method used to extract fatty acids and derivatize 
fatty acids to FAME should be explicitly stated and reference to the original studies 
of their use be cited.  
13) Analytical chemical fidelity. Methods should be reported in sufficient detail to 
establish unequivocally fatty acid identity and resolution. 
Reporting  
14) Fatty acid units. The rationale for primary reporting of fatty acid profile or absolute 
fatty acid concentration should be reported with respect to the hypotheses. 
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15) Data interconvertibility. Regardless of the choice of primary reporting method, all 
reports should include sufficient data to cfonvert relative to absolute concentrations 
and vice versa. 
16) Fatty acid base. The base of total fatty acids used in profile calculations should be 
specified, and the range of fatty acids marked in Table 1, particularly those in 
Category A should be reported to enable secondary calculations and interpretation. 
17) Relative response calibration. In practice, response factors should be evaluated 
daily. 
18) Internal standards. Rationale and procedure for IS should be reported, when used. 
19) Fatty acid identity. The identity of all FAME must be established for accurate 
analysis, and methods reported in the paper or supplementary materials.  
20) Comprehensive analysis. When LC/MS is necessary, panels of fatty acids 
encompassing at least the same range that are routine in GC should be analyzed 
qualitatively and quantitatively.  
21) Minimal detectable limits. Limits of detection or lower limits of quantification should 
be reported when fatty acids are not detected/quantified. 
22) Quality Control. Reports should specify QC procedures used for sample analyses. 
  
  
 
62 
Figure legend. 
Figure 1. Major fatty acids according to blood lipid pools according to global data (5). Full fatty 
acid compositions are available in Supplemental Table 3. 
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Supplemental Table 1. Fatty acids
1
 Reported by Laboratories Participating in each of the NIST FAQAP* 
Exercises
2
  
 
Exercise 1
3
 
Based on four samples 
11 labs reporting 
Exercise 2
4
 
Based on six samples 
14 labs reporting 
Exercise 3
5
 
Based on four samples 
12 labs reporting 
 (% of laboratories reporting within each exercise) 
14:0 100 86 92 
16:0 100 93 92 
18:0 100 93 92 
20:0 91 71 58 
22:0 100 79 67 
24:0 100 79 67 
14:1n-5 73 64 58 
16:1n-7 100 93 92 
18:1n-7 82 76 75 
18:1n-9 100 93 92 
20:1n-9 82 64 42 
22:1n-9 64 50 33 
24:1n-9 91 71 67 
18:2n-6 100 93 92 
18:3n-6 91 70 67 
20:2n-6 73 50 50 
20:3n-6 91 71 75 
20:4n-6 100 100 100 
22:4n-6 91 74 75 
22:5n-6 82 58 58 
18:3n-3 100 89 92 
20:5n-3 100 100 100 
22:5n-3 100 93 92 
22:6n-3 91 93 100 
*National Institute of Standards and Technology fatty acid Quality Assurance Program 
1
Two systems are in use for designating the double bond structure of straight chain monoene and 
homoallylic PUFA (non-conjugated, all methylene-interrupted double bonds). The IUPAC system uses  
“n-x” where n equals the number of carbons in the molecule, x is the number of the carbon of the double 
bond furthest from the carboxyl group and the “-“ is a minus sign:  for instance 18:3n-6 is read “eighteen 
three n minus six” and 18-6 = 12 where the last double bond is found. The omega notation introduced by 
Holman (his footnote 1) (103) numbers carbons atoms from the terminal methyl end; 18:3ω3 is read 
“eighteen three omega three”.  The two systems are equivalent in their designation of fatty acid structure 
for monoene and homoallylic PUFA. 
2
Fatty acids were derived from serum. 
3
Schantz MM, Powers CD, Schleicher R. Interlaboratory Analytical Comparison Study of Total Fatty  
Acid Concentrations in Human Serum: Results for Exercise 01: QA12FASER01. Gaithersburg, MD: 
NISTIR, 2013.  
4
Schantz MM. Interlaboratory Analytical Comparison Study of Fatty Acid Concentrations in Human 
Serum: Results for Exercise 02: QA15FASER02. Gaithersburg, MD: 2015. NISTIR 8086. 
5
Schantz MM. Interlaboratory Analytical Comparison Study of Fatty Acid Concentrations in Human 
Serum: Results for Exercise 03: QA16FASER03. Gaithersburg, MD: 2016. NISTIR 8086.  
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Supplemental Table 2. Additional fatty acids reported by Laboratories Participating in each of the 
NIST FAQAP* Exercises 2 and 3  
 
Exercise 2
1 
Based on six samples 
14 labs reporting 
Exercise 3
2 
Based on four samples 
12 labs reporting 
 
(% of laboratories reporting within each 
exercise) 
6:0  7 n.a.
3 
8:0  14 8 
10:0  27 17 
12:0  49 25 
26:0  7 8 
10:1n-1  7 8 
11:0  7 n.a. 
13:0  7 n.a. 
15:0  36 33 
17:0  43 42 
19:0  14 17 
21:0  20 17 
23:0  29 25 
12:1  14 17 
12:1n-7  7 8 
16:1n-7t  6 8 
16:1n-9  7 8 
18:1n-7t  7 n.a. 
18:1n-9t  11 n.a. 
18:1n-12  7 n.a. 
18:1n-12t  11 n.a. 
17:1  7 8 
26:1  7 8 
18:2n-6 9c,11t 7 10 
20:3n-9  7 8 
18:4n-3  7 8 
20:3n-3  21 21 
20:4n-3  14 17 
22:2n-6  14 19 
Phytanic acid (Δ3,7,11,15-methyl 16:0) 8 10 
Pristanic acid (Δ2,6,10,14-methyl 15:0) 7 19 
*National Institute of Standards and Technology Fatty Acid Quality Assurance Program 
1
Schantz MM. Interlaboratory Analytical Comparison Study of Fatty Acid Concentrations in  
Human Serum: Results for Exercise 02: QA15FASER02. Gaithersburg, MD: 2015. NISTIR 8086. 
2
Schantz MM. Interlaboratory Analytical Comparison Study of Fatty Acid Concentrations in  
Human Serum: Results for Exercise 03: QA16FASER03. Gaithersburg, MD: 2016. NISTIR 8086. 
3
n.a. = not applicable; exercise 3 did not request information on these fatty acids 
  
  
 
65 
Supplemental Table 3. Fatty acid Composition of Various Blood Pools and Reporting Percentages based 
on Global fatty acid Database (Fatty Acid Data is Relative weight % of Total Fatty Acids)  
 
Erythrocytes Plasma Total Lipids Plasma PL Whole Blood 
 122 studies 107 studies 118 studies 12 studies 
 
Mean ± SD 
Report 
%  
Mean ± SD 
Report 
% 
Mean ± SD 
Report 
% 
Mean ± SD 
Report 
% 
         
14:0 0.49 ± 0.26 25 1.12 ± 0.67 39 0.40 ± 0.26 28 1.35 ± 0.77 33 
16:0 22.32 ± 2.91
1 
65 22.08 ± 3.44 58 27.02 ± 3.66 55 23.32 ± 3.36 50 
18:0 15.23 ± 2.56 63 7.61 ± 1.74 58 13.74 ± 1.41 55 10.99 ± 0.87 50 
20:0 0.42 ± 0.40 11 0.31 ± 0.20 15 0.26 ± 0.29 25 0.32 ± 0.10 33 
22:0 1.14 ± 0.60 10 0.79 ± 0.51 13 1.36 ± 0.89 10 0.68 ± 0.21 25 
24:0 2.40 ± 1.85 13 0.70 ± 0.74 12 0.93 ± 0.53 10 1.51 ± 0.87 33 
14:1n-5 0.35 ± 0.39 3 0.32 ± 0.37 9 0.23 ± 0.30 2 0.13
2
 8 
16:1n-7 1.04 ± 1.53 26 2.22 ± 0.77 43 0.67 ± 0.62 35 1.72 ± 0.35 42 
18:1n-7 2.47 ± 4.20 11 1.75 ± 0.30 11 1.57 ± 0.21 17 1.78 ± 0.12 33 
18:1n-9 13.69 ± 2.48 63 20.12 ± 3.15 58 10.45 ± 1.94 55 18.25 ± 3.19 50 
20:1n-9 0.25 ± 0.16 11 0.31 ± 0.21 11 0.24 ± 0.19 18 0.23 ± 0.06 17 
22:1n-9 0.46 ± 0.49 3 0.30 ± 0.40 7 1.00 ± 1.66 3 0.29 ± 0.20 8 
24:1n-9 2.44 ± 1.90 16 0.83 ± 0.34 12 1.52 ± 0.96 12 1.13 ± 0.24 25 
18:2n-6 10.42 ± 2.80 80 27.48 ± 5.52 80 20.37 ± 3.05 74 21.68 ± 2.57 67 
18:3n-6 0.50 ± 1.87 24 0.36 ± 0.12 28 0.29 ± 0.72 26 0.28 ± 0.10 33 
20:2 n-6 0.35 ± 0.12 16 0.64 ± 1.26 16 0.41 ± 0.20 28 0.47 ± 0.33 17 
20:3n-6 1.83 ± 0.60 61 1.27 ± 0.48 44 2.88 ± 0.60 47 1.49 ± 0.28 50 
20:4n-6 12.89 ± 2.55 84 6.11 ± 1.70 84 9.29 ± 2.12 79 8.74 ± 1.79 67 
22:4n-6 2.95 ± 1.07 51 0.35 ± 0.20 18 0.40 ± 0.18 31 0.77 ± 0.40 42 
22:5n-6 0.79 ± 0.70 29 0.38 ± 0.25 15 0.27 ± 0.18 31 0.30 ± 0.02 17 
18:3n-3 0.35 ± 0.32 66 0.62 ± 0.29 75 0.23 ± 0.16 60 0.48 ± 0.12 67 
20:5n-3 0.95 ± 0.88 98 1.28 ± 1.12 98 1.47 ± 1.19 92 0.94 ± 0.52 92 
22:5n-3 2.19 ± 0.73 77 0.64 ± 0.33 59 1.01 ± 0.22 58 0.97 ± 0.16 58 
22:6n-3 4.43 ± 2.05 99 2.74 ± 1.69 100 4.21 ± 1.87 95 2.31 ± 0.45 92 
1
Fatty acid concentrations are often expressed to a set number of decimal places to capture an 
appropriate number of significant figures for low abundance fatty acids. This leads to excess significant 
figures for high abundance fatty acids since in general at most two significant figures should be reported 
for SDs.  
2
Only one study reported value, SD determination not possible. 
